Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 1912-1916, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, J. X.
Right arrow Articles by Lashkari, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, J. X.
Right arrow Articles by Lashkari, D.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Oak Ridge Conference
Right arrow Proteomics and Protein Markers
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2001;47:1912-1916.)
© 2001 American Association for Clinical Chemistry, Inc.

Oak Ridge Conference

High-Throughput Genomic and Proteomic Analysis Using Microarray Technology

Joe Xi Huang1, Dorothy Mehrens1, Rick Wiese1, Sandy Lee1, Sun W. Tam1, Steve Daniel1, James Gilmore1, Michael Shi1 and Deval Lashkari1a

1 Genometrix Inc., 2700 Research Forest Dr., The Woodlands, TX 77381.

aAuthor for correspondence. Fax 781-207-7883; e-mail dlashkari{at}genometrix.com.


Abstract

Background: High-density microarrays are ideally suited for analyzing thousands of genes against a small number of samples. The next step in the discovery process is to take the resulting genes of interest and rapidly screen them against thousands of patient samples, tissues, or cell lines to further investigate their involvement in disease risk or the response to medication.

Methods: We used a microarray technology platform for both single-nucleotide polymorphisms (SNPs) and protein expression. Each microarray contains up to 250 elements that can be customized for each application. Slides contained either a 16- or 96-microarray format (4000–24 000 elements per slide), allowing the corresponding number of samples to be rapidly processed in parallel.

Results: Results for SNP genotyping and protein profiling agreed with results of restriction fragment length polymorphism (RFLP) analysis or ELISA, respectively. Genotyping analyses, using the microarray technology, on large sample sets over multiple polymorphisms in the NAT2 gene were in full agreement with traditional methodologies, such as sequencing and RFLP analysis. The multiplexed protein microarray had correlation coefficients of 0.82–0.99 (depending on analyte) compared with ELISAs.

Conclusions: The integrated microarray technology platform is adaptable and versatile, while offering the high-throughput capabilities needed for drug development and discovery applications.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. A. G. Agundez, K. Golka, C. Martinez, S. Selinski, M. Blaszkewicz, and E. Garcia-Martin
Unraveling Ambiguous NAT2 Genotyping Data
Clin. Chem., August 1, 2008; 54(8): 1390 - 1394.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
P. Chavan, K. Joshi, and B. Patwardhan
DNA Microarrays in Herbal Drug Research
Evid. Based Complement. Altern. Med., December 1, 2006; 3(4): 447 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Maekawa, T. Nagaoka, T. Taniguchi, H. Higashi, H. Sugimura, K. Sugano, H. Yonekawa, T. Satoh, T. Horii, N. Shirai, et al.
Three-Dimensional Microarray Compared with PCR-Single-Strand Conformation Polymorphism Analysis/DNA Sequencing for Mutation Analysis of K-ras Codons 12 and 13
Clin. Chem., August 1, 2004; 50(8): 1322 - 1327.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
J. A. Macoska
The Progressing Clinical Utility of DNA Microarrays
CA Cancer J Clin, January 1, 2002; 52(1): 50 - 59.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.